Opevesostat clinical trials
Also written MK-5684 and ODM-208.
How each study uses opevesostat is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the opevesostat studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
13 studies that test it; most in 2024 (5)
| Year | Studies |
|---|---|
| 2018 | 1 |
| 2023 | 3 |
| 2024 | 5 |
| 2025 | 3 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 13 · Other 0
Merck Sharp & Dohme LLC (12) · Orion Corporation, Orion Pharma (1)
Often tested with
Tested in the same studies.
Megestrol Acetate (1) · Megestrol (1) · Medroxyprogesterone Acetate (1) · Medroxyprogesterone (1) · Tamoxifen (1) · Letrozole (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test opevesostat.
- Nov 2027A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015)Phase 2 · Merck Sharp & Dohme LLC
Studies
Open first, then newest update. How each study uses opevesostat is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 13
- Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)RecruitingPhase 3Merck Sharp & Dohme LLCNCT06136624Written as Opevesostat
- A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)RecruitingPhase 3Merck Sharp & Dohme LLCNCT06136650Written as Opevesostat
- A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015)RecruitingPhase 2Merck Sharp & Dohme LLCNCT06979596Written as Opevesostat
- Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A)Active, not recruitingPhase 1/2Merck Sharp & Dohme LLCNCT06353386Written as Opevesostat
- Safety and Pharmacokinetics of ODM-208 in Patients With Metastatic Castration-resistant Prostate CancerActive, not recruitingPhase 1/2Orion Corporation, Orion PharmaNCT03436485Written as ODM-208
- A Drug-Drug Interaction Study of Itraconazole and Opevesostat (MK-5684) in Healthy Adult Male Participants (MK-5684-017)CompletedPhase 1Merck Sharp & Dohme LLCNCT07548606Written as Opevesostat
- A Study of Opevesostat (MK-568)4 in Japanese Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-005)CompletedPhase 1Merck Sharp & Dohme LLCNCT06104449Written as Opevesostat
- A Study of Opevesostat (MK-5684) in China Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) (MK-5684-001)CompletedPhase 1Merck Sharp & Dohme LLCNCT06136598Written as Opevesostat
- A Study to Evaluate Opevesostat (MK-5684) in Male Participants With Moderate Hepatic Impairment (MK-5684-009)CompletedPhase 1Merck Sharp & Dohme LLCNCT06860243Written as Opevesostat
- A Study to Evaluate the Effect of MK-5684 in Male Participants With Severe Renal Impairment (RI) and With End-stage Renal Disease (ESRD) (MK-5684-010)CompletedPhase 1Merck Sharp & Dohme LLCNCT06814132Written as MK-5684
- A Drug-Drug Interaction Study of Carbamazepine and Opevesostat (MK-5684) in Healthy Adult Male Participants (MK-5684-012)CompletedPhase 1Merck Sharp & Dohme LLCNCT06633419Written as Opevesostat
- A Study of the Absorption, Distribution, Metabolism, and Elimination of Opevesostat (MK-5684) in Healthy Adult Male Participants (MK-5684-008)CompletedPhase 1Merck Sharp & Dohme LLCNCT06566989Written as [¹⁴C]Opevesostat
- A Drug-Drug Interaction Study of Diltiazem and MK-5684 in Healthy Adult Male Participants (MK-5684-011)CompletedPhase 1Merck Sharp & Dohme LLCNCT06554639Written as MK-5684
Given beside what is tested · 2 — opevesostat is usual care or a partner of the new treatment
- MK-2870-U01 Substudy 1: A Clinical Trial of Sacituzumab Tirumotecan to Treat Prostate Cancer (MK-2870-01A)Not yet recruitingPhase 1/2Merck Sharp & Dohme LLCNCT07908524Written as Opevesostat
- A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)RecruitingPhase 1/2Merck Sharp & Dohme LLCNCT06863272Written as Opevesostat
Codes
What other systems call opevesostat · ClinicalTrials.gg INT014372
- UNII (FDA) 1Z7MAV4KQCOPEVESOSTATOne source FDA
- NCI Thesaurus C156744OpevesostatOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 1Z7MAV4KQC | OPEVESOSTAT | One source FDA |
| NCI Thesaurus | C156744 | Opevesostat | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.